UTILIZATION STUDY OF DABIGATRAN ETEXILATE IN HOSPITALIZED PATIENTS

被引：0

作者：

Lopez Isabel, Cuesta ^{[1
]}

Silveira Eva, Delgado ^{[1
]}

Vicedo Teresa, Bermejo ^{[1
]}

Gonzalez Juana, Benedi ^{[1
]}

机构：

[1] Univ Complutense Madrid, Dept Farmacol, E-28040 Madrid, Spain

来源：

ATENCION FARMACEUTICA | 2012年 / 14卷 / 03期

关键词：

DABIGATRAN ETEXILATE; UTILIZATION STUDY; THROMBOEMBOLISM; VENOUS; SURGICAL PATIENT; PROPHYLAXIS; TOTAL KNEE REPLACEMENT; TOTAL HIP-REPLACEMENT; VENOUS THROMBOEMBOLISM; ORAL ANTICOAGULANTS; PREVENTION; RIVAROXABAN; ENOXAPARIN; TRIAL;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: To define the utilization profile of dabigatran etexilate in hospitalized patients. Method: Four-month observational prospective utilization study of the type prescription-indication. Data were obtained from pharmacological treatments of the electronic prescribing program, analytics and patients' clinical records. We reviewed their adaptation to the drug's data sheet and the hospital's utilization protocol. We recorded any adverse drug reactions. Results: 138 patients began treatment with dabigatran etexilate. In 89.13% of patients, dabigatran was prescribed for the approved indication in the data sheet, while in 10.87% it was used for other indications. 57.24% of prescriptions were adapted to the hospital's protocol and the data sheet. Conclusion: The use of dabigatran has been adequate for the majority of patients.

引用

页码：174 / 178

页数：5

共 50 条

[1] Utilization Study of Dabigatran Etexilate in Hospitalized Patients
Cuesta Lopez, Isabel
Delgado Silveira, Eva
Bermejo Vicedo, Teresa
Benedi Gonzalez, Juana
ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA, 2012, 78 (03): : 371 - 386
[2] Dabigatran etexilate
不详
AUSTRALIAN PRESCRIBER, 2009, 32 (02) : 51 - 52
[3] Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation: A Prospective Study
Larock, Anne-Sophie
Mullier, Francois
Sennesael, Anne-Laure
Douxfils, Jonathan
Devalet, Berangere
Chatelain, Christian
Dogne, Jean-Michel
Spinewine, Anne
ANNALS OF PHARMACOTHERAPY, 2014, 48 (10) : 1258 - 1268
[4] Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves
McKellar, Stephen H.
Abel, Stuart
Camp, Christopher L.
Suri, Rakesh M.
Ereth, Mark H.
Schaff, Hartzell V.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2011, 141 (06) : 1410 - 1416
[5] Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement
Samama, Charles-Marc
Rosencher, Nadia
Kleine, Eva
Feuring, Martin
Brueckmann, Martina
Clemens, Andreas
Gullberg, Jenny
Frostick, Simon P.
THROMBOSIS RESEARCH, 2016, 143 : 103 - 110
[6] The evolving role of dabigatran etexilate in clinical practice
Hellenbart, Erika
Drambarean, Beatrice
Lee, James
Nutescu, Edith A.
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (13) : 2053 - 2072
[7] Dabigatran Etexilate
Mark Sanford
Greg L. Plosker
Drugs, 2008, 68 : 1699 - 1709
[8] Advances in oral anticoagulants: focus on dabigatran etexilate
Hazlewood, Kathleen A.
Weiland, Christy M.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2010, 3 (06) : 727 - 737
[9] DABIGATRAN ETEXILATE IN VENOUS THROMBOEMBOLISM
Ferrer, Elisa
DRUGS OF TODAY, 2009, 45 (10) : 715 - 724
[10] Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
Stangier, Joachim
Clemens, Andreas
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2009, 15 : 9S - 16S

← 1 2 3 4 5 →